Take a fresh look at your lifestyle.

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound © Reuters. FILE PHOTO: Paxlovid, Pfizer’s anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken in Medford, Massachusetts, U.S., May 12, 2022. REUTERS/Brian Snyder/Illustration/

(Reuters) -The U.S. Food and Drug Administration (FDA) has ordered Pfizer Inc (NYSE:) to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.

The drugmaker must produce initial results of a randomized controlled trial of a second course of the antiviral by Sept. 30 next year, the FDA told Pfizer in a letter dated Aug. 5.

The regulator said a formal plan for the clinical trial is expected to be finalized this month.

Pfizer is “working with the FDA to finalize a protocol to study patients who may be in need of retreatment,” and will provide details when available, a company spokesperson said.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More